Spero Therapeutics, Inc. Payments of Stock Issuance Costs
Spero Therapeutics, Inc. (SPRO) reported Payments of Stock Issuance Costs of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2023-03-30
- Spero Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2022-12-31 was $0.00.
- Spero Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2021-12-31 was -$163.00K, a 143.70% decline year-over-year.
- Spero Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2021-09-30 was $265.00K, a 239.74% increase year-over-year.
- Spero Therapeutics, Inc. payments of stock issuance costs for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Spero Therapeutics, Inc. payments of stock issuance costs for fiscal 2021 was $248.00K, a 73.98% decline from fiscal 2020.
- Spero Therapeutics, Inc. payments of stock issuance costs for fiscal 2020 was $953.00K, a 503.16% increase from fiscal 2019.
- Spero Therapeutics, Inc. payments of stock issuance costs for fiscal 2019 was $158.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $0.00 10-K · filed 2023-03-30 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-10 | |||
| 2021-12-31 | -$163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $102.00K derived: sum of 2 quarters · filed 2023-03-30 | $211.00K derived: sum of 3 quarters · filed 2023-03-30 | $248.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $265.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $374.00K derived: sum of 2 quarters · filed 2022-11-14 | $411.00K 10-Q · filed 2022-11-14 | $784.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $109.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $146.00K 10-Q · filed 2022-08-10 | $519.00K derived: sum of 3 quarters · filed 2022-08-10 | $597.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $37.00K 10-Q · filed 2022-05-16 | $410.00K derived: sum of 2 quarters · filed 2022-05-16 | $488.00K derived: sum of 3 quarters · filed 2022-05-16 | $638.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $373.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $451.00K derived: sum of 2 quarters · filed 2022-03-31 | $601.00K derived: sum of 3 quarters · filed 2022-03-31 | $953.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $78.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $228.00K derived: sum of 2 quarters · filed 2021-11-10 | $580.00K 10-Q · filed 2021-11-10 | $580.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $150.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $502.00K 10-Q · filed 2021-08-05 | $502.00K derived: sum of 3 quarters · filed 2021-08-05 | $581.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $352.00K 10-Q · filed 2021-05-06 | $352.00K derived: sum of 2 quarters · filed 2021-05-06 | $431.00K derived: sum of 3 quarters · filed 2021-05-06 | $494.00K derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $79.00K derived: sum of 2 quarters · filed 2021-03-11 | $142.00K derived: sum of 3 quarters · filed 2021-03-11 | $158.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | $79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $142.00K derived: sum of 2 quarters · filed 2020-11-05 | $158.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $63.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $79.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $16.00K 10-Q · filed 2020-05-08 | |||
| 2018-09-30 | $749.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $996.00K 10-Q · filed 2019-11-04 | ||
| 2018-06-30 | $247.00K 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $3.57M 10-K · filed 2019-03-14 | ||
| 2017-09-30 | $507.00K 10-Q · filed 2017-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |